Janux CEO exercises options for 7,000 JANX shares

Janux Therapeutics, Inc. President and CEO David Alan Campbell exercised stock options to acquire 7,000 shares of common stock at an exercise price of $4.21 per share.

Rhea-AI Filing Summary

Janux Therapeutics, Inc. President and CEO David Alan Campbell exercised stock options to acquire 7,000 shares of common stock at an exercise price of $4.21 per share. Following the transaction on July 8, 2026, he holds 388,582 common shares directly and 697,550 stock options remaining, with the exercised option series immediately exercisable and expiring on March 9, 2031.

Insights

Equity Compensation Analyst

CEO executed a routine option exercise, increasing direct share ownership without any reported open-market sale.

President and CEO David Alan Campbell exercised options for 7,000 shares of common stock at an exercise price of $4.21 per share on July 8, 2026. This is coded as an exercise or conversion of a derivative security, not as an open-market purchase or sale.

After the exercise, he directly holds 388,582 common shares and retains 697,550 stock options, which are noted as immediately exercisable and expiring on March 9, 2031. With no sales or tax-withholding dispositions reported, this filing reflects a straightforward compensation-related equity exercise rather than a change in strategic ownership posture.

Insider Trade Summary

7,000 shares exercised/converted

Exercise 2 txns

Insider Campbell David Alan

Role President and CEO

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1	7,000	$0.00	$0.00
Exercise	Common Stock	7,000	$4.21	$29K

Holdings After Transaction: Stock Option (right to buy) — 697,550 contracts (Direct); Common Stock — 388,582 shares (Direct)

Footnotes (1)

1. F1. Immediately exercisable.

Key Figures

Options Exercised: 7,000 shares Exercise Price: $4.21 per share Common Shares Held After: 388,582 shares +2 more

5 metrics

Options Exercised 7,000 shares Stock options exercised into common stock on July 8, 2026

Exercise Price $4.21 per share Exercise or conversion price of the stock options

Common Shares Held After 388,582 shares Direct common stock holdings following the transaction

Options Remaining After 697,550 options Stock option balance after exercising 7,000 options

Option Expiration March 9, 2031 Expiration date of the exercised option grant

Key Terms

Stock Option (right to buy), derivative security, exercise price, immediately exercisable

4 terms

Stock Option (right to buy) financial

"security_title: "Stock Option (right to buy)""

derivative security financial

"transaction_code_description: "Exercise or conversion of derivative security""

A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.

exercise price financial

"conversion_or_exercise_price: "4.2100""

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

immediately exercisable financial

"Footnote: "Immediately exercisable.""

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did JANX CEO David Alan Campbell report in this Form 4?

David Alan Campbell reported exercising 7,000 stock options for Janux Therapeutics (JANX) common stock on July 8, 2026, converting them into 7,000 shares at an exercise price of $4.21 per share.

Did the JANX CEO buy or sell shares on the open market in this filing?

The JANX CEO did not report any open-market buys or sells. He exercised 7,000 stock options coded as a derivative exercise, increasing his share ownership without a reported sale transaction.

How many Janux Therapeutics (JANX) shares does the CEO hold after this transaction?

After the transaction, the CEO directly holds 388,582 shares of Janux Therapeutics common stock. In addition, he retains 697,550 stock options following the reported option exercise on July 8, 2026.

What was the exercise price of the JANX CEO’s stock options?

The exercised stock options had an exercise price of $4.21 per share. Exercising 7,000 options at this price converted them into 7,000 shares of Janux Therapeutics common stock under the reported Form 4.

When do the exercised Janux Therapeutics (JANX) stock options expire?

The option series involved in this Form 4 expires on March 9, 2031. A footnote indicates the options are immediately exercisable, and 7,000 of these options were exercised on July 8, 2026.

How many Janux Therapeutics (JANX) options does the CEO still hold after exercising?

Following the reported exercise, the CEO continues to hold 697,550 stock options tied to Janux Therapeutics common stock. This reflects his remaining derivative equity position after converting 7,000 options into common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/10/2026 - 08:00 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Campbell David Alan

(Last) (First) (Middle)

C/O JANUX THERAPEUTICS, INC.

10955 VISTA SORRENTO PARKWAY, SUITE 200

(Street)

SAN DIEGO CALIFORNIA 92130

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Janux Therapeutics, Inc. [ JANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/08/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/08/2026		M		7,000	A	$4.21	388,582	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.21	07/08/2026		M			7,000	(1)	03/09/2031	Common Stock	7,000	$0	697,550	D

Explanation of Responses:

1. Immediately exercisable.

	/s/ James Pennington, Attorney-in-Fact	07/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)